Analysis of the Effectiveness of Risk Management Applied to Adverse Events during ATG Treatment for Aplastic Anemia
Objective:To observe the efficacy of risk management in the prevention and treatment of adverse events during treatment with anti-human thymocyte immunoglobulin(ATG)free in patients with aplastic anemia.Methods:127 patients with aplastic anemia who received ATG treatment in the hospital from August 2020 to March 2022 were selected as the study subjects,and they were divided into the intervention group(64 cases,clinical nursing care was implemented based on risk management)and the routine group(63 cases,only clinical basic nursing care was implemented)using the computerized random grouping method.The occurrence of adverse events,improvement of symptoms and prognosis during treatment were compared between the two groups.Results:The incidence of adverse events in the intervention group was lower than that in the control group,and the difference was statistically significant(x2=5.433,P＜0.05).The difference between T lymphocyte subsets in the intervention group and the control group was statistically significant(t=9.832,10.197,28.313,3.712;P＜0.05).Hemoglobin(Hb),red blood cell count(RBC),platelet count(PLT),and percentage of neutrophils(NE)were higher in the intervention group than in the control group,and the difference was statistically significant(t=2.345,14.917,16.204,12.200;P＜0.05).The recurrence rate and mortality rate of the disease in the intervention group during the follow-up period were lower than those in the control group,and the score of the Brief Healthy Living Conditions Scale(SF-36)was higher than that of the control group,with statistically significant differences(x2=7.832,7.685,t=11.386;P＜0.05).Conclusion:Implementing risk management during ATG therapy in patients with aplastic anemia is positive for reducing the incidence of adverse events,enhancing treatment efficacy,improving immune function and prognosis,and enhancing quality of life.
Aplastic anemiaRisk managementImmunoglobulin against human thymocytesAdverse eventsPrognosis
万方数据
维普
